Sign in
Taking people in United StatesPhase 4

Empagliflozin compared with placebo for people with gout and high uric acid

Tests empagliflozin against placebo on uric acid levels in adults with gout.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
Status
Recruiting
Phase
Phase 4
People taking part
60 people, planned
Started
1 Jul 2026
Expected to end
28 Feb 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Empagliflozin 10 mg
  • Placebo
Record updated
5 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with gout and high uric acid in the blood. It tests whether empagliflozin lowers uric acid compared with a placebo (dummy pill) over 3 months.

Age
18 to 80 years
Sex
Men and women
Disease stage
Gout that meets the ACR/EULAR gout criteria, with at least 1 gout flare in the last 12 months.
Earlier treatment
People taking colchicine or NSAID drugs to prevent flares cannot join. People using anti-obesity drugs cannot join.
Biomarker or test result
Serum urate (uric acid in the blood) level ≥ 6mg/dl.

Main reasons for not taking part

  • Kidney function (eGFR) below 20ml/min
  • Active heart or blood vessel disease, or type-1 diabetes
  • Pregnant or breastfeeding women
  • Past ketoacidosis, end-stage or decompensated liver disease, or active cancer
  • Basal-bolus or multiple daily insulin injections, or loop diuretics (water pills)

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Provision of signed and dated informed consent form
  • Fulfilling American College of Rheumatology [ACR]/European Alliance of Associations for Rheumatology [EULAR] gout criteria
  • 1+ gout flares in last 12 months
  • Serum urate level ≥ 6mg/dl
  • Males and females; Age 18-80
  • Willingness to adhere to the study intervention procedures

Who cannot take part

  • Colchicine or nonsteroidal anti-inflammatory drug [NSAID] prophylaxis
  • Use of anti-obesity drugs
  • active cardiovascular disease [CVD], type-1 diabetes
  • Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation. [History of ketoacidosis, end-stage or decompensated liver disease, active cancer]
  • Estimated Glomerular Filtration Rate [eGFR] <20ml/min
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • pregnant and lactating women
  • Basal-bolus or multiple daily injection insulin regimens, or loop diuretics

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • Massachusetts General HospitalBoston, United StatesContact: Hyon K Choi, MDTaking people

About the trial

What the trial wants to find out

SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors [SGLT2i] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate [SU] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein [hsCRP] and interleukin 6 [IL-6], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.

The 2 groups in the trial

  • Empagliflozin 10mgTreatment being tested

    Participants in this arm will take empagliflozin 10mg daily

    Treatment: Empagliflozin 10 mg

  • PlaceboPlacebo, for comparison

    Participants in this arm will take a placebo daily

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SAVE-Care (SGLT2i As Novel Gout Care) Trial
Plain-language title
Empagliflozin compared with placebo for people with gout and high uric acidGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06674109, who can take part
Record updated
5 August 2026